Endothelium protecting properties of taurin in chronic heart failure with type 2 diabetes

Стаценко, М. Е.; Туркина, С. В.; Шилина, Н Н; Винникова, А А

doi:10.15829/1728-8800-2016-2-38-44

Cited by 5 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results of studies presented in the literature confirm the possibility of using taurine in the prevention of a number of cardiovascular diseases [7,10,11]. It has been established that the wide spectrum of action of taurine is due to its metabolic nature and the regulating effect of this compound on the functional state of the organs and body systems, as well as various types of metabolism [6][7][8]10].…”

Section: Resultsmentioning

confidence: 90%

Modern Possibilities of Metabolic Therapy in Improving the Quality of Life in Patients with Postinfarction Cardiosclerosis

Irina¹,

Vladimir²

2019

AJIM

View full text Add to dashboard Cite

95 patients with postinfarction cardiosclerosis and angina pectoris II and III functional classes were examined. The study included patients who refused intervention revascularization. The main group included 48 patients who were added taurine (Dibikor 750 mg / day) to enhance the effect of basic therapy, and the comparison group included 47 patients who received standard therapy and placebo. The duration of treatment was 3 months. The study demonstrated positive effects of taurine that was confirmed by significant improvements in the following indicators: subjective status, indicators of the Seattle questionnaire, echocardiographic parameters, cardiac arrhythmias. There was a decrease in the severity of fatigue by 2 times, a decrease in the intensity of complaints of palpitations by 72.3%, a decrease in the severity of dyspnea by 30.0% and a severity of pain in the heart area by 50%. Indicators of most scales of the Seattle questionnaire in patients of the main group at the end of the study significantly exceeded (p <0.05) the corresponding values in patients of the comparison group. In patients whose treatment was used taurine, a significant improvement in inotropic function was noted (the ejection fraction is significantly higher than in the comparison group, respectively 56.0 ± 1.8 and 53.5 ± 1.1%, p <0,05), the bathmotropic and chronotropic myocardial functions improved, which was shown by a 45% decrease in the number of ventricular extrasystoles, a 57% decrease in the frequency of supraventricular heart rhythm disturbances, a decrease in the incidence rate of ST segment depression (in the main group the number of episodes was significantly lower than p <0,05 than in the comparison group). The use of taurine in the complex treatment of patients with exertional angina, after suffering a myocardial infarction, is safe and not accompanied by side effects. Taurine is advisable to include in the complex treatment of patients with exertional angina pectoris, who have had a myocardial infarction in order to improve the myocardial inotropic function, enhance the antiarrhythmic and lipid-lowering effects of the basic therapy. The recommended dose of Taurine is 750 mg per day as a supplement to standard therapy with a duration of therapy of at least 3 months.

show abstract

Section: Resultsmentioning

confidence: 90%

Modern Possibilities of Metabolic Therapy in Improving the Quality of Life in Patients with Postinfarction Cardiosclerosis

Irina¹,

Vladimir²

2019

AJIM

View full text Add to dashboard Cite

show abstract

“…Учитывая то, что ОС является важнейшим звеном пато-генеза большинства ССЗ, показания к при-менению Мексикора значительно шире, чем у других метаболических цитопротекторов. Уникальное сочетание свойств Мексикора обусловило наличие у препарата цитопро-текторного эффекта, поэтому препарат ши-роко применяется не только в кардиологии, но и в неврологии, эндокринологии [34][35][36][37][38].…”

Section: рис 1 химическая структура оксиметилэтилпири-дина сукцинатаunclassified

“…Назначение циопротекора Мексикора также оказалось эффективным и при ле-чении сочетанной кардио-эндокринной па-тологии [43,44]. Отмечено его позитивное влияние на углеводный и липидный об-мен, снижение скорости прогрессирования атеросклероза, уменьшение выраженности ОС.…”

Section: рис 1 химическая структура оксиметилэтилпири-дина сукцинатаunclassified

“…Отмечено его позитивное влияние на углеводный и липидный об-мен, снижение скорости прогрессирования атеросклероза, уменьшение выраженности ОС. Опыт применения Мексикора у боль-ных ХСН на фоне СД 2 типа показал, что в сравнении с контролем у пациентов ос-новной группы отмечались лучшие показа-тели клинического состояния пациентов, то-лерантности к физической нагрузке, отме-чалась достоверно положительная динами-ка показателей качества жизни по данным Миннесотского опросника [43,45]. Согласно данным Стаценко М. Е. и соавт., примене-ние Мексикора в составе базисной терапии у больных с ХСН и метаболическим син-дромом улучшает клиническое состояние па-циентов, уменьшает функциональный класс ХСН, повышает толерантность к физиче-ской нагрузке благодаря антиангинально-му эффекту, увеличению сократимости мио-карда и уменьшением выраженности диа-столической дисфункции.…”

Section: рис 1 химическая структура оксиметилэтилпири-дина сукцинатаunclassified

“…Особенно важ-но также и то, что в ходе исследова-ний был выявлен фармакологический синер-гизм комбинации Мексикор+статины. От-мечен и гепатопротективный эффект дан-ной комбинации, показатели цитолиза, за-кономерно увеличивающиеся при приеме статинов, в случае дополнительного при-ема Мексикора, напротив, снижались, до-стигая нормальных значений [45]. Спектр применения цитопротекторов в эндокрино-логии, безусловно, может быть расширен.…”

Section: рис 1 химическая структура оксиметилэтилпири-дина сукцинатаunclassified

See 2 more Smart Citations

IS THERE ANY POINT INCARDIOMETABOLIC THERAPY IN THE TREATMENT OF PATIENTS WITH CORONARY ARTERY DISEASE AND TYPE 2 DIABETES MELLITUS? (literature review)

Zhuravlyova

Лопина

2016

PEP

View full text Add to dashboard Cite

The article focused on coronary artery disease, as it takes a leading place in the structure of cardiovascular morbidity and mortality. The article described pathogenetic mechanisms of influence the ischemia on the myocardium, particularly of energy production in the myocardium in norm and ischemia. The basic therapeutic strategies to reducing ischemia were described. Discussed reasons for the persistence of pain in the heart after «successful» revascularization. Substantiated along with the standard therapy the use of cardiometabolic medications in cytoprotection ischemia. The article described the classification cytoprotectors on the specifics of the pharmacological effect. Substantiated clinical application of Mexicor.

show abstract

TAURIN INFLUENCE ON CLINICAL COURSE OF STAbLE ANGINA IN POSTINFARCTION CARDIOSCLEROSIS PATIENTS

Vasilieva

Резван

2018

Russ J Cardiol

View full text Add to dashboard Cite

Aim. Study of efficacy and safety of taurin in management of stable angina patients with postinfarction cardiosclerosis.Material and methods. Totally, 95 postinfarction cardiosclerosis patients included, with stable angina of II and III functional class. The patients that were included, had refused revascularization. To the main group, 48 were included with added taurin (Dibicor, “PIK-Pharma”, Russia, 750 mg daily), and to comparison group — 47 patients that were taking standard treatment and placebo. Treatment duration 3 months. Results. Clinical efficacy of taurin in postinfarction cardiosclerosis and stable angina is confirmed by significant improvement of the following parameters: subjective state (decreased fatigue, less complaints on palpitation, less severity of dyspnea and rarer angina attacks), of the life quality parameters by Seattle questionnaire; echocardiographic parameters, normalized cardiac rhythm. Postive changes achieved on the basis therapy with taurin, remained for 3 months after drug discontinuation.Conclusion. Positive influence of taurin on clinical and instrumental parameters of patients make it to recommend its prescription for stable angina treatment in postinfarction cardiosclerosis patients.

show abstract

Endothelium protecting properties of taurin in chronic heart failure with type 2 diabetes

Cited by 5 publications

References 8 publications

Modern Possibilities of Metabolic Therapy in Improving the Quality of Life in Patients with Postinfarction Cardiosclerosis

Modern Possibilities of Metabolic Therapy in Improving the Quality of Life in Patients with Postinfarction Cardiosclerosis

IS THERE ANY POINT INCARDIOMETABOLIC THERAPY IN THE TREATMENT OF PATIENTS WITH CORONARY ARTERY DISEASE AND TYPE 2 DIABETES MELLITUS? (literature review)

TAURIN INFLUENCE ON CLINICAL COURSE OF STAbLE ANGINA IN POSTINFARCTION CARDIOSCLEROSIS PATIENTS

Contact Info

Product

Resources

About